Lenexa Kan. Dr. Ogden joined Agouron Pharmaceuticals, Inc. as a founding scientist at its inception in 1984, where he held positions of Group Leader of Medicinal Chemistry, Principal Scientist, and Senior Director of Scientific Development. He was a team member in the HIV project which led to the discovery and development of Nelfinavir (Viracept®).
Responsibilities in Scientific Development included presenting Agouron R&D activities to potential corporate partners and investors, assessing technology and compound acquisitions, including the therapeutic vaccine Remune and the reverse transcriptase inhibitor Capravirine. He was also responsible for the process by which new drug targets were selected and projects initiated, and communicating research and clinical activities to clinicians, other healthcare providers and patient groups post merger with Pfizer. He has gone on to become a recognized leader in the HIV clinical research community.